Telix Pharmaceuticals Limited (TLX)
| Market Cap | 4.06B +25.3% |
| Revenue (ttm) | 890.79M +33.5% |
| Net Income | 33.50M +183.8% |
| EPS | 0.10 +174.8% |
| Shares Out | 339.78M |
| PE Ratio | 121.31 |
| Forward PE | 304.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,449 |
| Open | 11.93 |
| Previous Close | 11.31 |
| Day's Range | 11.85 - 12.10 |
| 52-Week Range | 6.28 - 13.11 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 19.93 (+66.78%) |
| Earnings Date | Oct 15, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $19.93, which is an increase of 66.78% from the latest price.
News
Telix Pharmaceuticals Slides: FY 2026
Telix Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 22, 2026.
Telix upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Telix Pharmaceuticals (TLX) to Outperform from Sector Perform with a price target of A$21, up from A$19.
RBC upgrades Telix to Outperform on ITM deal benefits
RBC Capital analyst Craig Wong-Pan upgraded Telix Pharmaceuticals (TLX) to Outperform from Sector Perform with a price target of A$21, up from A$19. The firm likes the company’s acquisition of…
Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash
Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts.
Telix Pharmaceuticals Limited to Merge with ITM Isotope Technologies Munich SE Transcript
Telix Pharmaceuticals Limited to Merge with ITM Isotope Technologies Munich SE Transcript
Telix To Merge With ITM In Deal Valued At Up To $2.35 Billion
(RTTNews) - Telix Pharmaceuticals (TLX) has agreed to merge with ITM Isotope Technologies Munich SE, a company specializing in radioisotope production and radiopharmaceutical development, in a transac...
Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX,TLX.AX) announced that it signed an agreement to acquire privately held ITM Isotope Technologies Munich SE in a transaction valued at up to US$2.35 billion,...
Telix Pharmaceuticals to Acquire ITM Isotope Technologies for $1.65 Billion
Telix Pharmaceuticals to Acquire ITM Isotope Technologies for $1.65 Billion
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement ...
Telix Pharmaceuticals Transcript: M&A announcement
The merger creates a vertically integrated radiopharmaceutical leader with enhanced manufacturing, supply chain, and late-stage therapeutic assets. The $1.65B deal includes $700M in performance-based milestones and is expected to be EBITDA positive by 2027, with significant synergies and global reach.
Telix Pharmaceuticals Slides: M&A announcement
Telix Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 20, 2026.
Telix Pharmaceuticals Press release: M&A announcement
Telix Pharmaceuticals issued a press release on September 20, 2026, disclosing material business information to investors.
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.
Telix Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A vertically integrated radiopharma business leverages strong imaging sales to fund a late-stage pipeline in urology and neuro-oncology. Recent FDA approval of Pixclara expands the imaging portfolio, while the BiPASS and ProstACT GLOBAL 2 phase III trials advance, with key data readouts expected early next year.
Telix Pharmaceuticals Shares Soar 11.26% as FDA Approves Its Novel Pixclara Brain Cancer Imaging Drug
Telix Pharmaceuticals shares rose 11.26% after the FDA approved Pixclara, its brain cancer imaging drug, extending a rally driven by the regulatory milestone.
Telix Pharmaceuticals Limited at Morgan Stanley Global Healthcare Conference Transcript
Telix Pharmaceuticals Limited at Morgan Stanley Global Healthcare Conference Transcript
Telix Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Recent FDA approval for PIXCLARA and ongoing label expansion efforts highlight innovation in imaging and therapeutics, while strategic acquisitions and vertical integration strengthen distribution and operational capabilities. Growth in Precision Medicine, transformative clinical trials, and strong financials position the company for continued leadership in radiopharma.
Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children
(RTTNews) - Telix Pharmaceuticals Limited (TLX) announced that the U.S. Food and Drug Administration (FDA) has approved Pixclara (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomogr...
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Adm...
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and G...
Telix Completes Patient Enrollment In BiPASS Trial, Aligns With FDA On NDA Filing; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Wednesday reported completion of patient enrollment in the Phase 3 BiPASS study, evaluating its commer...
6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
(RTTNews) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies, which...
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3...
Telix Appoints Gill As Board Chairman
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Tuesday announced the appointment of David Gill as Chair of the Board, effective immediately.
Telix Appoints David Gill as Chair
MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appoi...